Tobramycin disposition in ICU patients receiving a once daily regimen: population approach and dosage simulations.
about
Pharmacokinetic and pharmacodynamic issues for antimicrobial therapy in patients with cancerPopulation pharmacokinetics of imipenem in critically ill patients with suspected ventilator-associated pneumonia and evaluation of dosage regimensHow do we use therapeutic drug monitoring to improve outcomes from severe infections in critically ill patients?Two mechanisms of killing of Pseudomonas aeruginosa by tobramycin assessed at multiple inocula via mechanism-based modeling.Novel approach to optimize synergistic carbapenem-aminoglycoside combinations against carbapenem-resistant Acinetobacter baumanniiAssessing Predictive Performance of Published Population Pharmacokinetic Models of Intravenous Tobramycin in Pediatric Patients.Optimization of Synergistic Combination Regimens against Carbapenem- and Aminoglycoside-Resistant Clinical Pseudomonas aeruginosa Isolates via Mechanism-Based Pharmacokinetic/Pharmacodynamic Modeling.Pharmacological considerations for the proper clinical use of aminoglycosides.Approaches for dosage individualisation in critically ill patients.Therapeutic drug monitoring of anti-infective agents in critically ill patients.Clinically relevant concentrations of fosfomycin combined with polymyxin B, tobramycin or ciprofloxacin enhance bacterial killing of Pseudomonas aeruginosa, but do not suppress the emergence of fosfomycin resistance.The ADMIN-ICU survey: a survey on antimicrobial dosing and monitoring in ICUs.Resistance suppression by high-intensity, short-duration aminoglycoside exposure against hypermutable and non-hypermutable Pseudomonas aeruginosa.Population pharmacokinetics of tobramycin in patients with and without cystic fibrosis.Combating carbapenem-resistant Acinetobacter baumannii by an optimized imipenem plus tobramycin dosage regimen - prospective validation via hollow fiber infection and mathematical modeling.Evaluation of Pharmacokinetic/Pharmacodynamic Model-Based Optimized Combination Regimens against Multidrug-Resistant Pseudomonas aeruginosa in a Murine Thigh Infection Model by Using Humanized Dosing Schemes.Aminoglycoside Concentrations Required for Synergy with Carbapenems against Pseudomonas aeruginosa Determined via Mechanistic Studies and Modeling.Optimization and evaluation of piperacillin plus tobramycin combination dosage regimens against Pseudomonas aeruginosa for patients with altered pharmacokinetics via the hollow-fiber infection model and mechanism-based modeling.
P2860
Q26825326-E9AAB87D-132F-4644-A288-0B00F85E1EDEQ34570886-C2B939B0-CD21-4951-BCBA-0795E4798C57Q34894900-E7F105EA-1B9C-45BA-8EAB-FAFDE8186812Q35168882-2AF77B06-E99A-4915-A06F-FCBB62E34FC3Q35168931-5C7C3818-1947-42BD-B791-DD97A284E579Q36933449-14671CD3-504C-4B00-A984-56F6AECF1C98Q37538623-268B1F33-210F-4498-8FF1-4361C4BAE0A8Q37956403-E993D164-5E9D-48B1-8265-C7347C6B7428Q38125209-297E5C3D-4932-4436-BCF6-2A212BEE2838Q38790740-88051474-823D-469C-A880-60CE3602A4EDQ40697349-95A3FC13-3091-4BD5-918B-E2BA9F2FFF52Q41110594-A41CEF92-D8F5-4F33-8488-D68752793E8FQ42717931-043E44EA-4E8F-4454-AEC3-789B24B0D184Q46172261-F0DDB03F-6343-44E9-B9FB-5DF7F716F4E8Q47562492-276FB843-F63F-42F7-8978-8A91C95054ABQ47656109-1464DFA1-4ADF-469B-ABEF-D2F35F2555F2Q47691167-36F473A8-CD81-4D1D-9169-2BCF97B969D4Q49792113-C42E9461-8580-426E-8813-3F3542B0DA2C
P2860
Tobramycin disposition in ICU patients receiving a once daily regimen: population approach and dosage simulations.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Tobramycin disposition in ICU ...... proach and dosage simulations.
@ast
Tobramycin disposition in ICU ...... proach and dosage simulations.
@en
Tobramycin disposition in ICU ...... proach and dosage simulations.
@nl
type
label
Tobramycin disposition in ICU ...... proach and dosage simulations.
@ast
Tobramycin disposition in ICU ...... proach and dosage simulations.
@en
Tobramycin disposition in ICU ...... proach and dosage simulations.
@nl
prefLabel
Tobramycin disposition in ICU ...... proach and dosage simulations.
@ast
Tobramycin disposition in ICU ...... proach and dosage simulations.
@en
Tobramycin disposition in ICU ...... proach and dosage simulations.
@nl
P2093
P2860
P1476
Tobramycin disposition in ICU ...... proach and dosage simulations.
@en
P2093
Bernard Georges
Georges Houin Pharmd
Jean-Marie Conil
Olivier Fourcade
Pierre Cougot
Stéphanie Ruiz
Sylvie Saivin
Thierry Seguin
Thomas Rival
P2860
P356
10.1111/J.1365-2125.2010.03793.X
P407
P577
2011-01-01T00:00:00Z